Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

The consensus recommendations in 2018 from The Chinese Society of Hematology (CSH)
on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem …

Abstract The American Society for Transplantation and Cellular Therapy (ASTCT) published
its first white paper on indications for autologous and allogeneic hematopoietic cell …

Abstract Approximately 20,000 hematopoietic cell transplantation (HCT) procedures are
performed in the United States annually. With advances in transplantation technology and …

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is widely used to treat
malignant hematological neoplasms and non-malignant hematological disorders …

Postremission therapy in patients with acute myeloid leukemia (AML) may consist of
continuing chemotherapy or transplantation using either autologous or allogeneic stem …

Allogeneic blood or bone-marrow transplantation (alloBMT) is a potentially curative
treatment for a variety of haematological malignancies and nonmalignant diseases …

Background Non-T-cell depleted haploidentical hematopoietic stem cell transplantation
(HaploSCT) is being increasingly used in acute lymphoblastic leukemia (ALL) with …

Background The introduction of donors other than HLA-matched siblings has been a pivotal
change in stem cell transplantation. We aimed to assess the evolution of outcomes within …

Background Haploidentical donor (HID) hematopoietic stem cell transplantation (HSCT) is
an alternative treatment method for severe aplastic anemia (SAA) patients lacking suitable …